-
Potential benefits of l-serine in children with GRIN2B loss-of-function variants: Randomized n-of-1 trials
den Hollander, B., Rothuizen-Lindenschot, M., Le, H. L., Ramautar, J. R., Müller, A. R., Geertjens, L., Vaz, F. M., van Eeghen, A. M., Cornel, M. C., Jacobs, B. A. W., Bruining, H., van de Ven, P. M., Brands, M. M. & van Karnebeek, C. D., Dec 2025, In: Molecular Genetics and Metabolism. 146, 4, p. 109268 109268.Research output: Contribution to journal › Article › Academic › peer-review
-
Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials
Müller, A. R., den Hollander, B., van de Ven, P. M., Roes, K. C. B., Geertjens, L., Bruining, H., van Karnebeek, C. D. M., Jansen, F. E., de Wit, M. C. Y., Ten Hoopen, L. W., Rietman, A. B., Dierckx, B., Wijburg, F. A., Boot, E., Brands, M. M. G. & van Eeghen, A. M., 1 Dec 2024, In: BMC psychiatry. 24, 1, p. 23 23.Research output: Contribution to journal › Article › Academic › peer-review
-
Corrigendum to “Effectiveness of L-serine supplementation in children with a GRIN2B loss-of-function mutation: Rationale and protocol for single patient (n-of-1) multiple cross-over trials” [Contemp. Clin. Trials Commun. 36 (2023)/ DOI: 10.1016/j.conctc.2023.101233] (Contemporary Clinical Trials Communications (2023) 36, (S2451865423001795), (10.1016/j.conctc.2023.101233))
Hollander, B. D., Rothuizen-Lindenschot, M., Geertjens, L., Vaz, F. M., Brands, M. M., le, H. L., van Eeghen, A. M., van de Ven, P. M., Cornel, M. C., Jacobs, B. A. W., Bruining, H. & van Karnebeek, C. D., Apr 2024, In: Contemporary Clinical Trials Communications. 38, p. 101264 101264.Research output: Contribution to journal › Comment/Letter to the editor › Academic
- All publications
